US20120122950A1 - Libraries of 1-(sulfonyl)-n-phenylpyrrolidine-2-carboxamides for drug discovery - Google Patents

Libraries of 1-(sulfonyl)-n-phenylpyrrolidine-2-carboxamides for drug discovery Download PDF

Info

Publication number
US20120122950A1
US20120122950A1 US13/334,337 US201113334337A US2012122950A1 US 20120122950 A1 US20120122950 A1 US 20120122950A1 US 201113334337 A US201113334337 A US 201113334337A US 2012122950 A1 US2012122950 A1 US 2012122950A1
Authority
US
United States
Prior art keywords
alkyl
formula
compounds
group
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/334,337
Other languages
English (en)
Inventor
Josep Castells Boliart
David Enrique MIGUEL CENTENO
Marta Pascual Gilabert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Universitari de Ciencia i Tecnologia
Original Assignee
Institut Universitari de Ciencia i Tecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Universitari de Ciencia i Tecnologia filed Critical Institut Universitari de Ciencia i Tecnologia
Assigned to INSTITUT UNIV. DE CIENCIA I TECNOLOGIA, S. A. reassignment INSTITUT UNIV. DE CIENCIA I TECNOLOGIA, S. A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BOLIART, JOSEP CASTELLS, CENTENO, DAVID ENRIQUE MIGUEL, GILABERT, MARTA PASCUAL
Publication of US20120122950A1 publication Critical patent/US20120122950A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/08—Liquid phase synthesis, i.e. wherein all library building blocks are in liquid phase or in solution during library creation; Particular methods of cleavage from the liquid support

Definitions

  • the field of the invention is medicinal chemistry.
  • the invention relates to 1-(sulfonyl)-N-phenylpyrrolidine-2-carboxamides which can be therapeutically active.
  • Novel compounds are continually sought after to treat and prevent diseases and disorders.
  • Pharmaceutical companies interested in developing new active molecules develop and purchase libraries of chemical compounds in order to screen their biological or pharmacological activity against a particular target, aiming at the identification of new industrially useful products. Therefore, there is a market of customer companies for which the acquisition of novel libraries of chemical compounds, not already biologically explored, is a key issue. Therefore, for the companies whose core business is the design and preparation of libraries of chemical compounds, their commercialization has a clear industrial interest.
  • library is applied to a group of compounds which are structurally related by a main base structure (scaffold), but which are distinguishable by the changes in the specific substitute groups linked to the base structure.
  • the libraries of compounds described in this invention are useful for exploring the chemical space, for incrementing the structural diversity of valuable molecules in the pharmaceutical sector and for increasing the elements of structural recognition in order to study their interaction with biological targets of interest in the pharmaceutical or medical chemistry field.
  • the molecules may be therapeutically useful as anti-inflammatory or anticoagulation agents, among many other applications
  • the present invention is useful for a systematic synthesis of large libraries of compounds with industrial applicability.
  • the present invention is useful for making libraries and subsequently optimising the compounds considered as relevant according to the target of interest.
  • Libraries described in this invention are useful for being biologically and pharmaceutically explored, and therefore to contribute in the research and identification of new drug leads able to modulate the functional activity of a biological target, since these molecules are new sources of chemical diversity not explored up to date.
  • the libraries of the present invention can be explored by means of any known method of biological screening. These methods comprise, but are not limited to, receptor affinity assays, ELISA assays, “southern”, “western” and “northern blot”, and competitive binding assays.
  • Virtual (database) screening is an important component of the computer-based search of novel lead compounds.
  • the primary VS premise is to screen a database of molecules computationally using structural descriptors that relate in some way to potential biological activity. A subset of database molecules found to match these descriptors can then be selected for subsequent biological analysis.
  • pharmacophore searching is one of the most widely applied VS methods.
  • pharmacophore is defined as a critical arrangement of molecular fragments or features creating a necessary, although not sufficient, condition for biological activity and receptor affinity.
  • the present invention concerns libraries of chemical compounds wherein each member of said library is a compound of formula (I)
  • the invention further relates to methods for the preparation of the libraries of compounds where each member of said library is a compound of formula (I), the N-oxides, addition salts, quaternary amines, metal complexes, and stereochemically isomeric forms thereof, their intermediates, and the use of the intermediates in the preparation of the compounds of formula (I).
  • the invention also relates to the use of libraries of compounds of formula (I), or N-oxide, addition salt, quaternary amine, metallic complex and stereochemically isomeric forms thereof, for the manufacture of a medicament for the treatment of a disease or conditions such as inflammation or coagulation.
  • the present invention relates to the use of the compound of formula (I), or N-oxide, addition salt, quaternary amine, metallic complex and stereochemically isomeric forms thereof, for use in the treatment of a disease or conditions such as inflammation or coagulation.
  • the invention relates to a method for treating a disease or conditions such as inflammation or coagulation in a warm-blooded animal, said method comprising administering an effective amount of compound of formula (I), or N-oxide, addition salt, quaternary amine, metallic complex and stereochemically isomeric forms thereof.
  • libraries of compounds of formula (I) or “libraries of compounds where each member of the library is a compound of formula (I)” or “the present libraries” or “the present compounds” or similar terms is meant to include in the libraries of compounds of formula (I), all and each of the subgroups thereof, N-oxides, addition salts, quaternary amines, metallic complex and stereochemically isomeric forms.
  • the present disclosure also includes the prodrugs of compounds of formula (I).
  • halo is generic to fluoro, chloro, bromo and iodo.
  • polyhaloC 1-6 alkyl as a group or part of a group, e.g. in polyhaloC 1-6 alkoxy, is defined as mono- or polyhalo substituted C 1-6 alkyl, in particular C 1-6 alkyl substituted with up to one, two, three, four, five, six, or more halo atoms, such as methyl or ethyl with one or more fluoro atoms, for example, difluoromethyl, trifluoromethyl, trifluoroethyl. Preferred is trifluoromethyl.
  • perfluoroC 1-6 alkyl groups which are C 1-6 alkyl groups wherein all hydrogen atoms are replaced by fluorine atoms, e.g. pentafluoroethyl.
  • the halogen atoms may be the same or different.
  • C 1-4 alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as for example methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-1-propyl;
  • C 1-6 alkyl encompasses C 1-4 alkyl radicals and the higher homologues thereof having 5 or 6 carbon atoms such as, for example, 1-pentyl, 2-pentyl, 3-pentyl, 1-hexyl, 2-hexyl, 2-methyl-1-butyl, 2-methyl-1-pentyl, 2-ethyl-1-butyl, 3-methyl-2-pentyl, and the like.
  • C 1-6 alkyl is C 1-4 alkyl.
  • C 2-6 alkenyl as a group or part of a group defines straight and branched chained hydrocarbon radicals having saturated carbon-carbon bonds and one double bond, and having from 2 to 6 carbon atoms, such as, for example, ethenyl (or vinyl), 1-propenyl, 2-propenyl (or allyl), 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-2-propenyl, 2-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 2-methyl-2-butenyl, 2-methyl-2-pentenyl and the like.
  • C 2-6 alkenyl is C 2-4 alkenyl.
  • C 3-7 cycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • C 1-6 alkoxy means C 1-6 alkyloxy wherein C 1-6 alkyl is as defined above.
  • radical positions on any molecular moiety used in the definitions may be anywhere on such moiety as long as it is chemically stable.
  • Radicals used in the definitions of the variables include all possible positional isomers unless otherwise indicated.
  • pyridyl includes 2-pyridyl, 3-pyridyl and 4-pyridyl
  • pentyl includes 1-pentyl, 2-pentyl and 3-pentyl.
  • the compounds of formula (I) making up the libraries of the present invention may have one or more centers of chirality and may exist as stereochemically isomeric forms.
  • stereochemically isomeric forms as used herein defines all the possible compounds made up of the same atoms bonded by the same sequence of atoms but having different three-dimensional structures which are not interchangeable, which the compounds of formula (I) may possess.
  • the chemical designation of a compound encompasses the mixture of all possible stereochemically isomeric forms, which said compound may possess. Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound. All stereochemically isomeric forms of the compounds of the present invention both in pure form or mixed with each other are intended to be embraced within the scope of the present invention.
  • Pure stereoisomeric forms of the compounds and intermediates of the libraries of the invention can be obtained by the application of art-known procedures.
  • enantiomers may be separated from each other by the selective crystallization of their diastereomeric salts with optically active acids or bases. Examples thereof are tartaric acid, dibenzoyltartaric acid, ditoluoyltartaric acid and camphorsulfonic acid.
  • enantiomers may be separated by chromatographic techniques using chiral stationary phases.
  • Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically.
  • a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.
  • the diastereomeric racemates of the compounds of formula (I) can be obtained separately by conventional methods.
  • Appropriate physical separation methods that may advantageously be employed are, for example, selective crystallization and chromatography, e.g. column chromatography.
  • the present invention is also intended to include all isotopes of atoms occurring on the present compounds.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include tritium and deuterium.
  • isotopes of carbon include C-13 and C-14.
  • ester prodrugs that are hydrolysable in vivo and are derived from those compounds of formula (I) having a hydroxy or a carboxyl group.
  • An in vivo hydrolysable ester is an ester, which is hydrolysed in the human or animal body to produce the parent acid or alcohol.
  • esters for carboxy include C 1-6 alkoxymethyl esters for example methoxymethyl, C 1-6 alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C 3-8 cycloalkoxycarbonyloxyC 1-6 alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters for example 5-methyl-1,3-dioxolen-2-onylmethyl; and C 1-6 alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyl-oxyethyl which may be formed at any carboxy group in the compounds of this invention.
  • An in vivo hydrolysable ester of a compound of the formula (I) containing a hydroxy group includes inorganic esters such as phosphate esters and a-acyloxyalkyl ethers and related compounds which as a result of the in vivo hydrolysis of the ester breakdown to give the parent hydroxy group.
  • inorganic esters such as phosphate esters and a-acyloxyalkyl ethers and related compounds which as a result of the in vivo hydrolysis of the ester breakdown to give the parent hydroxy group.
  • a-acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy.
  • salts of the compounds of formula (I) are those wherein the counter-ion is pharmaceutically acceptable.
  • salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.
  • the pharmaceutically acceptable acid and base addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid and base addition salt forms which the compounds of formula (I) are able to form.
  • the pharmaceutically acceptable acid addition salts can conveniently be obtained by treating the base form with such appropriate acid.
  • Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic (i.e. ethanedioic), malonic, succinic (i.e.
  • butanedioic acid maleic, fumaric, malic (i.e. hydroxybutanedioic acid), tartaric, citric, methane sulfonic, ethanesulfonic, benzene sulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like acids.
  • salt forms can be converted by treatment with an appropriate base into the free base form.
  • the compounds of formula (I) containing an acidic proton may also be converted into their non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases.
  • Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. the benzathine, N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.
  • addition salt as used hereinabove also comprises the solvates which the compounds of formula (I) as well as the salts thereof, are able to form.
  • solvates are for example hydrates, alcoholates and the like.
  • One embodiment of the present invention relates to libraries of compounds of formula (I) or of any subgroup of compounds of formula (I), wherein one or more of the following conditions apply:
  • One embodiment of the present invention relates to libraries of compounds of formula (I) or of any subgroup of compounds of formula (I), wherein one or more of the following conditions apply:
  • amide derivative compound of formula [6] As shown in the above scheme 1, coupling of a compound of formula [4] with the primary amine compound of formula [5] gives the amide derivative compound of formula [6].
  • the coupling reaction occurs in an organic solvent, such as a chlorinated solvent, preferably dichloromethane, 1,2-dichloroethane or chloroform, at a temperature preferably between ⁇ 10° C. and 40° C., more preferably between 0° C. and 25° C.
  • Compound of formula [4] comprises a group —CO—R 4 in the form of an activated carboxyl derivative, such as acid chlorides, anhydrides, or active esters such as O-acylisoureas or acyloxyphosphonium derivatives.
  • R 6 group is a benzyl protecting group
  • the deprotection reaction comprises the chemoselective reduction of the metal hydride with a reductive agent such as NaBH 4 or Ca(BH 4 ) 2 in a polar protic solvent, such as ethanol or 2-propanol at a temperature preferably between ⁇ 10° C. and 25° C., more preferably between 0° C. and 10° C.
  • R 7 group is a methanesulfonyl activating group, and the reaction occurs in a chlorinated solvent, preferably dichloromethane, 1,2-dichloroethane or chloroform, in anhydrous or non anhydrous conditions, at a temperature preferably between ⁇ 10° C. and 40° C., more preferably between 0° C. and 25° C.
  • a chlorinated solvent preferably dichloromethane, 1,2-dichloroethane or chloroform
  • R 5 is an amino protecting group, carbamate, urea-type derivative, amide, cyclic imide, alkyl, aryl, imine, enamine or heteroatom.
  • the protecting group is tert-butoxycarbonyl group and the deprotecting agent is trifluoroacetic acid in a chlorinated solvent, preferably dichloromethane, 1,2-dichloroethane or chloroform, at a trifluoroacetic acid composition preferably between 5% and 90%, more preferably between 15% and 70%, at a temperature preferably between 0° C. and 45° C., more preferably between 10° C. and 30° C.
  • the reaction solvent is a chlorinated solvent, preferably dichloromethane, 1,2-dichloroethane or chloroform, or a polar aprotic solvent, preferably acetonitrile, tetrahydrofuran, or dimethylformamide, at a temperature preferably between 0° C. and 40° C., more preferably between 10° C. and 25° C.
  • the reaction solvent is a chlorinated solvent, preferably dichloromethane, 1,2-dichloroethane or chloroform, or a polar aprotic solvent, preferably acetonitrile, tetrahydrofuran, or dimethylformamide, at a temperature preferably between 0° C. and 40° C., more preferably between 10° C. and 25° C.
  • R 6 group is a benzyl protecting group
  • the deprotection reaction comprises the chemoselective reduction of the metal hydride with an reductive agent such as NaBH 4 or Ca(BH 4 ) 2 in a polar protic solvent, such as ethanol or 2-propanol at a temperature preferably between ⁇ 10° C. and 25° C., more preferably between 0° C. and 10° C.
  • reaction occurs in the presence of an inorganic or organic base, such as sodium hydride, potassium tert-butoxide or lithium diisopropylamide, at a temperature preferably between ⁇ 78° C. and 60° C., more preferably between -40° C. and 0° C.
  • the reaction solvent is a polar aprotic solvent, preferably acetonitrile, tetrahydrofuran, dimethylformamide, or dimethylsulfoxide.
  • an embodiment of the present invention relates to a process for preparing a library of compounds of formula (I) as described herein, said process comprising a) reacting in a suitable medium compound of formula (II) with a compound of formula (III)
  • the suitable medium of the reaction in step b) is in the presence of an inorganic or organic base, such as sodium hydride, potassium tert-butoxide or lithium diisopropylamide, at a temperature preferably between ⁇ 78° C. and 60° C., more preferably between ⁇ 78° C. and 25° C.
  • the reaction solvent is a polar aprotic solvent, preferably acetonitrile, tetrahydrofuran, dimethylformamide, or dimethylsulfoxide.
  • leaving group is preferably a halogen atom, more preferably bromine or chlorine.
  • activating group is preferably but not limited to a carboxyl activant in coupling reactions, preferably in the form of an acid chloride, anhydride, or active esters, such as O-acylisoureas or acyloxyphosphonium derivatives.
  • 3-chlorobenzenecarboperoxoic acid peroxoalkanoic acids, e.g. peroxoacetic acid, alkylhydroperoxides, e.g. tert-butyl hydro-peroxide.
  • Suitable solvents are, for example, water, lower alcohols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.
  • Diastereomers may be separated by physical methods such as selective crystallization and chromatographic techniques, e.g., counter-current distribution, liquid chromatography and the like.
  • the libraries of compounds of formula (I) may be obtained as racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures.
  • the racemic compounds of formula (I), which are sufficiently basic or acidic may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid, respectively chiral base. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali or acid.
  • An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase.
  • the compounds of the present invention or any of the subgroups thereof can be formulated in several pharmaceutical forms with the object of being administered.
  • suitable composition all compositions typically used for the administration of drugs can be mentioned.
  • a pharmaceutical composition of the present invention a therapeutically effective amount of the compound in particular, optionally in the form of an addition salt or metallic complex, as an active ingredient, is admixed with the pharmaceutically acceptable vehicle, where the vehicle may be present in several forms depending on the intended route of administration.
  • These pharmaceutical compositions are preferred in the form of a single dosage, particularly, for oral, rectal, percutaneous or parenteral injection administration.
  • any of the pharmaceutical means can be used such as, for example, water, glycols, oils, alcohols, and the like in the case of liquid oral preparations such as suspensions, syrups, mouthwashes, emulsions and solutions; or solid vehicles, such as starch, sugars, kaolin, lubricants, binding agents, disgregating agents and the like in the case of powders, pills, capsules and tablets. Due to its easy administration, tablets and capsules are the most advantageous forms for single dosage, in which case it is obvious that solid pharmaceutical vehicles are used.
  • the vehicle will often include sterile water, at least mostly, although other ingredients should be included, for example, for improving the solubility.
  • injectable solutions can be prepared where the vehicle comprises saline solutions, glucose solutions or a mixture of saline and glucose solutions.
  • injectable suspensions can also be prepared in which case suitable vehicle liquid, suspending agents and the like can be used.
  • suitable vehicle liquid, suspending agents and the like can be used.
  • preparations of solid forms which are intended to convert into liquid preparations just before their use.
  • the vehicle optionally comprises an enhancing agent for penetration and/or a suitable wetting agent, optionally combined with suitable additives of any kind in minor quantities, additives which are not significantly deleterious for the skin.
  • the compounds of the present invention or any subgroup thereof can be used as a drug.
  • Said use as a drug or method of treatment comprises administering to an individual an effective amount of the compound of formula (I) for combating conditions associated to different diseases, such as inflammation or coagulation,
  • the present invention relates to a method of treatment a disease or conditions such as inflammation or coagulation warm-blooded animals, said method including administering an effective amount of compound of formula (I) as indicated in the previous paragraphs, or of a compound from any of the compounds of formula (I).
  • One embodiment of the present invention concerns compounds of formula (VI) or any subgroup of compounds of formula (VI), and the salts and stereoisomers thereof, wherein one or more of the following conditions apply:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Structural Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US13/334,337 2009-06-26 2011-12-22 Libraries of 1-(sulfonyl)-n-phenylpyrrolidine-2-carboxamides for drug discovery Abandoned US20120122950A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200901524 2009-06-26
ES200901524A ES2351323B1 (es) 2009-06-26 2009-06-26 Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para el descubrimiento de farmacos.
PCT/ES2010/070433 WO2010149820A1 (fr) 2009-06-26 2010-06-28 Bibliothèques de n-phényl-1-sulfonyl-2-pyrrolidinecarboxamides pour la découverte de médicaments

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2010/070433 Continuation-In-Part WO2010149820A1 (fr) 2009-06-26 2010-06-28 Bibliothèques de n-phényl-1-sulfonyl-2-pyrrolidinecarboxamides pour la découverte de médicaments

Publications (1)

Publication Number Publication Date
US20120122950A1 true US20120122950A1 (en) 2012-05-17

Family

ID=43386063

Family Applications (1)

Application Number Title Priority Date Filing Date
US13/334,337 Abandoned US20120122950A1 (en) 2009-06-26 2011-12-22 Libraries of 1-(sulfonyl)-n-phenylpyrrolidine-2-carboxamides for drug discovery

Country Status (4)

Country Link
US (1) US20120122950A1 (fr)
EP (1) EP2447249A4 (fr)
ES (1) ES2351323B1 (fr)
WO (1) WO2010149820A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455660B2 (en) 2009-06-25 2013-06-04 Institut Univ. De Ciencia I Tecnologia, S.A. 1-(sulfonyl)-N-phenylpyrrolidine-2-carboxamides for the identification of biological and pharmacological activity
US8569507B2 (en) 2009-06-25 2013-10-29 Institut Univ. De Ciencia I Technologia, S.A. N-(2-oxo-1-phenylpiperidin-3-yl)sulfonamides for the identification of biological and pharmacological activity
US8809584B2 (en) 2009-06-25 2014-08-19 Institut Univ. De Ciencia I Tecnologia, S.A. N-substituted-N-phenylethylsulfonamides for the identification of biological and pharmacological activity
EP4356909A1 (fr) * 2022-10-17 2024-04-24 Selabtec Sciences, SLU 1derives de (sulfonyl)-n-phenylpyrrolidine-2-carboxamides et leur utilisation

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2351452B1 (es) * 2009-07-01 2011-10-05 Institut Univ. De Ciència I Tecnologia, S.A. Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para la identificacion de actividad biologica y farmacologica.
CN103079563B (zh) 2010-08-24 2015-07-08 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的脯氨酸磺酰胺衍生物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469036B1 (en) * 1999-01-27 2002-10-22 Ortho-Mcneil Pharmaceutical, Inc. Peptidyl heterocyclic ketones useful as tryptase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1098514B (de) * 1956-12-15 1961-02-02 Hoechst Ag Verfahren zur Herstellung von N-substituierten Pyrrolidin-2-carbonsaeuren und deren Amiden
JPH09227512A (ja) * 1996-02-23 1997-09-02 Basf Ag 置換されたピロリジンの製法及び物質ビブリオテークの製法
US6939973B1 (en) 1999-02-09 2005-09-06 The Scripps Research Institute Glycoluril core molecules for combinatorial libraries
US6589978B2 (en) * 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469036B1 (en) * 1999-01-27 2002-10-22 Ortho-Mcneil Pharmaceutical, Inc. Peptidyl heterocyclic ketones useful as tryptase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Mijin et al., "Alkylation of N-substituted 2-phenylacetamides: Benzylation of N-(4-chlorophenyl)-2-phenylacetamide," J. Serb. Chem. Soc. 2004, 69(2):85-92. *
STN record of the compound with CAS Registry Number 1009793-13-8 (Entered STN on March 24, 2008). *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455660B2 (en) 2009-06-25 2013-06-04 Institut Univ. De Ciencia I Tecnologia, S.A. 1-(sulfonyl)-N-phenylpyrrolidine-2-carboxamides for the identification of biological and pharmacological activity
US8569507B2 (en) 2009-06-25 2013-10-29 Institut Univ. De Ciencia I Technologia, S.A. N-(2-oxo-1-phenylpiperidin-3-yl)sulfonamides for the identification of biological and pharmacological activity
US8809584B2 (en) 2009-06-25 2014-08-19 Institut Univ. De Ciencia I Tecnologia, S.A. N-substituted-N-phenylethylsulfonamides for the identification of biological and pharmacological activity
EP4356909A1 (fr) * 2022-10-17 2024-04-24 Selabtec Sciences, SLU 1derives de (sulfonyl)-n-phenylpyrrolidine-2-carboxamides et leur utilisation
WO2024083861A1 (fr) 2022-10-17 2024-04-25 Selabtec Sciences, Slu Dérivés 1-(sulfonyl)-n-phénylpyrrolidine-2-carboxamides et leur utilisation

Also Published As

Publication number Publication date
ES2351323B1 (es) 2011-10-05
WO2010149820A1 (fr) 2010-12-29
EP2447249A4 (fr) 2013-02-20
EP2447249A1 (fr) 2012-05-02
ES2351323A1 (es) 2011-02-03

Similar Documents

Publication Publication Date Title
WO2010087399A1 (fr) Antagonistes du récepteur de l'urotensine ii
US20120122950A1 (en) Libraries of 1-(sulfonyl)-n-phenylpyrrolidine-2-carboxamides for drug discovery
US8569507B2 (en) N-(2-oxo-1-phenylpiperidin-3-yl)sulfonamides for the identification of biological and pharmacological activity
US20120129888A1 (en) Libraries of n-(2-oxo-1-phenylpiperidin-3-yl)sulfonamides for drug discovery
US8809584B2 (en) N-substituted-N-phenylethylsulfonamides for the identification of biological and pharmacological activity
US8455660B2 (en) 1-(sulfonyl)-N-phenylpyrrolidine-2-carboxamides for the identification of biological and pharmacological activity
US20120122708A1 (en) Libraries of n-(2-oxo-1-phenylpiperidin-3-yl)sulfonamides for the identification of biological and pharmacological activity
US20120122709A1 (en) Libraries of 1-(sulfonyl)-n-phenylpyrrolidine-2-carboxamides for the identification of biological and pharmacological activity
JP5368556B2 (ja) 心臓血管疾患の処置のための新規ヘテロシクリル化合物
US20120122920A1 (en) Libraries of n-substituted-n-phenylethylsulfonamides for drug discovery
JP5663743B2 (ja) モチリン受容体作動活性を有するオキシインドール誘導体
US20120122710A1 (en) Libraries of n-substituted-n-phenylethylsulfonamides for the identification of biological and pharmacological activity
DE69813886T2 (de) Naphthalin derivate
JP2012519153A5 (fr)
US20060111392A1 (en) Substituted biaryl-carboxylate derivatives
AU2012309556A1 (en) Pyrrolidine-3-ylacetic acid derivative
JP2011510997A (ja) 新規ｓＥＨ阻害剤およびその使用
ES2351574A1 (es) Bibliotecas de n-fenetisulfonamidas-n-sustituidas para el descubrimiento de farmacos.

Legal Events

Date Code Title Description
AS Assignment

Owner name: INSTITUT UNIV. DE CIENCIA I TECNOLOGIA, S. A., SPA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOLIART, JOSEP CASTELLS;CENTENO, DAVID ENRIQUE MIGUEL;GILABERT, MARTA PASCUAL;REEL/FRAME:027641/0779

Effective date: 20120109

STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION